Vaxcell-Bio Therapeutics Co. Ltd
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Vaxcell-Bio Therapeutics Co. Ltd (323990) - Net Assets
Latest net assets as of September 2025: ₩65.22 Billion KRW
Based on the latest financial reports, Vaxcell-Bio Therapeutics Co. Ltd (323990) has net assets worth ₩65.22 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩70.50 Billion) and total liabilities (₩5.28 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩65.22 Billion |
| % of Total Assets | 92.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | 107.67% |
| 10-Year Change | N/A |
| Growth Volatility | 140.62 |
Vaxcell-Bio Therapeutics Co. Ltd - Net Assets Trend (2018–2024)
This chart illustrates how Vaxcell-Bio Therapeutics Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vaxcell-Bio Therapeutics Co. Ltd (2018–2024)
The table below shows the annual net assets of Vaxcell-Bio Therapeutics Co. Ltd from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩71.99 Billion | -13.77% |
| 2023-12-31 | ₩83.49 Billion | +257.92% |
| 2022-12-31 | ₩23.33 Billion | -22.45% |
| 2021-12-31 | ₩30.08 Billion | -13.23% |
| 2020-12-31 | ₩34.67 Billion | +282.17% |
| 2019-12-31 | ₩9.07 Billion | +174.38% |
| 2018-12-31 | ₩-12.20 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vaxcell-Bio Therapeutics Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3852739524000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩126.41 Billion | 175.58% |
| Total Equity | ₩71.99 Billion | 100.00% |
Vaxcell-Bio Therapeutics Co. Ltd Competitors by Market Cap
The table below lists competitors of Vaxcell-Bio Therapeutics Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Talga Group Ltd
PINK:TLGRF
|
$103.27 Million |
|
Apollo Pipes Limited
NSE:APOLLOPIPE
|
$103.29 Million |
|
Namsun Alumini
KO:008350
|
$103.30 Million |
|
AROAF
PINK:AROAF
|
$103.30 Million |
|
Beijing Liven Technology Co. Ltd.
SHE:001259
|
$103.19 Million |
|
Tornado Global Hydrovacs Ltd
V:TGH
|
$103.17 Million |
|
Bliss GVS Pharma Limited
NSE:BLISSGVS
|
$103.10 Million |
|
ReposiTrak
NASDAQ:TRAK
|
$103.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vaxcell-Bio Therapeutics Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 83,493,267,980 to 71,994,122,340, a change of -11,499,145,640 (-13.8%).
- Net loss of 10,623,545,780 reduced equity.
- Other factors decreased equity by 875,599,860.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-10.62 Billion | -14.76% |
| Other Changes | ₩-875.60 Million | -1.22% |
| Total Change | ₩- | -13.77% |
Book Value vs Market Value Analysis
This analysis compares Vaxcell-Bio Therapeutics Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩-1720.04 | ₩8290.00 | x |
| 2019-12-31 | ₩525.11 | ₩8290.00 | x |
| 2020-12-31 | ₩2304.10 | ₩8290.00 | x |
| 2021-12-31 | ₩1488.88 | ₩8290.00 | x |
| 2022-12-31 | ₩1532.37 | ₩8290.00 | x |
| 2023-12-31 | ₩3631.22 | ₩8290.00 | x |
| 2024-12-31 | ₩3142.51 | ₩8290.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vaxcell-Bio Therapeutics Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -559.45%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.07x
- Recent ROE (-14.76%) is below the historical average (-13.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-5.23 Billion |
| 2019 | -13.82% | 0.00% | 0.00x | 1.11x | ₩-2.16 Billion |
| 2020 | -11.49% | 0.00% | 0.00x | 1.02x | ₩-7.45 Billion |
| 2021 | -15.83% | 0.00% | 0.00x | 1.04x | ₩-7.77 Billion |
| 2022 | -29.26% | 0.00% | 0.00x | 1.04x | ₩-9.16 Billion |
| 2023 | -12.31% | -74865.79% | 0.00x | 1.02x | ₩-18.62 Billion |
| 2024 | -14.76% | -559.45% | 0.02x | 1.07x | ₩-17.82 Billion |
Industry Comparison
This section compares Vaxcell-Bio Therapeutics Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vaxcell-Bio Therapeutics Co. Ltd (323990) | ₩65.22 Billion | 0.00% | 0.08x | $103.22 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |